VIDEO: Many options for anti-obesity medications in the pipeline
Click Here to Manage Email Alerts
DALLAS — In this Healio video exclusive, Ania M. Jastreboff, MD, PhD, highlights several medications that may have a large impact on obesity care in the near future.
Jastreboff, an associate professor of medicine and pediatrics (endocrinology) at Yale University School of Medicine, director of the Yale Obesity Research Center and co-director of the Yale Center for Weight Management, said nutrient stimulated hormone-based medications are leading the charge with the new wave of anti-obesity medications. Once-weekly semaglutide (Wegovy, Novo Nordisk) has already been FDA approved for obesity care and tirzepatide (Mounjaro, Eli Lilly) is currently under FDA review. Jastreboff said other similar agents, including combination cagrilintide and semaglutide, or CagriSema (Novo Nordisk), retatrutide (Eli Lilly), orforglipron (Eli Lilly), survodutide (Boehringer Ingelheim and Zealand Pharma) and high-dose oral semaglutide 50 mg (Novo Nordisk) are all currently in phase 3 studies.
In addition, Jastreboff said providers should also keep an eye on another class of medications called activin-receptor inhibitors that may make an impact on obesity treatment in the years to come.
“Ultimately, we will have many tools to treat our patients with obesity just as we have many therapies to treat patients with hypertension or with type 2 diabetes,” Jastreboff said.
Collapse
Healio Interviews
Click Here to Manage Email Alerts